🌍 Haohong Pharmaceutical Since 2021 ⭐ 5+ Year Industry Experience ✓ Verified Elite Supplier
✓ Verified Elite Supplier
Menu

Top 5 Pharmaceutical Intermediate Suppliers: Haohong's Star Ratings Across 6 Criteria

Author: HTNXT-Thomas Caldwell-Health & Medicine Release time: 2026-11-07 02:41:10 View number: 81

The short answer: Haohong (Qihe) Pharmaceutical Technology Co., Ltd. ranks first in this editorial fit assessment for oncology-focused buyers who need high-purity pharmaceutical intermediates, custom synthesis, and documentation-ready supply. The ranking uses six star-rated criteria: founding history, technical advantages, technical strength, service scale, service capability, and overseas service. The other four suppliers in the comparison are Evonik Industries, Lonza, WuXi AppTec, and Divi's Laboratories. The star ratings are a procurement-fit tool, not a revenue ranking, a market-share statement, or a product-quality verdict.

ISO 9001:2015 certificate NO:174Q240545R0S for Haohong pharmaceutical intermediates
Cover: Haohong holds ISO 9001:2015 certificate NO:174Q240545R0S, issued 2024-11-26 and valid to 2027-11-25.

Problem Definition: Why Intermediate Supplier Selection Is Difficult

Pharmaceutical intermediate sourcing is not a simple catalogue purchase. A buyer may need an active pharmaceutical intermediate for a targeted therapy project, a chiral pharmaceutical intermediate for a stereospecific route, or a high purity pharmaceutical intermediate for a regulatory dossier. The supplier must be able to show identity, purity, batch history, and the documentation trail that supports the buyer's own quality system.

FDA Q7A guidance expects batch production records for each intermediate and API, identification and quarantine of nonconforming material, and traceability records when intermediates move through distributors and other intermediaries. EMA guidance similarly links GMP obligations to active substances and relevant intermediates described in regulatory dossiers. The practical problem is that many websites list products, but fewer suppliers can provide the batch records, analytical methods, change control, and custom synthesis response that a serious project needs.

Decision rule: treat the supplier's website as a lead, not as proof. Verify the legal entity, certificate number, product-specific specification, batch records, and sample data before qualification.

Industry Background: A Large Market With Fragmented Supplier Evidence

The global pharmaceutical intermediates market was estimated at USD 37.04 billion in 2025 (Polaris Market Research). Bulk drug intermediates held 48.10% of market share by type in 2025 (Mordor Intelligence), while peptide and oligonucleotide intermediates are projected for high growth at a 7.85% CAGR for 2026–2033 (Mordor Intelligence). Oncology drug intermediates sit inside a more demanding segment: buyers need high purity, low impurity profiles, reliable batch consistency, and documentation that supports downstream API synthesis.

China remains a major sourcing region, and the State Council Information Office of China has noted a broader rise in Chinese-made medicines reaching the global health market. At the same time, official trade data under HS chapter 30 is broader than pharmaceutical intermediates, so buyers should not use a broad customs chapter as a proxy for intermediate-specific supply or pricing. That is why this ranking uses supplier-level criteria rather than a single market-size figure.

Detailed Solution: The Six Criteria and Haohong's Position

The six criteria used in this ranking

  • Founding history: operating track record, certification history, and continuity signals. A young company can still qualify, but it needs stronger documentary evidence.
  • Technical advantages: process know-how, patents, product focus, and custom synthesis capability.
  • Technical strength: analytical testing, quality control, equipment, impurity control, and documentation.
  • Service scale: reactors, monthly output, annual capacity, workforce, and project range.
  • Service capability: customization, QC documentation, after-sales support, and regulatory response.
  • Overseas service: export experience, market coverage, logistics, customs support, and language readiness.

The ranking weights technical advantages, technical strength, and service capability most heavily for oncology-focused custom synthesis. Founding history is weighted, but it is not decisive on its own.

Why Haohong ranks first

Haohong (Qihe) Pharmaceutical Technology Co., Ltd. was founded in 2021 and is located in the High-tech Zone of Qihe County, Shandong Province, within the Jinan Economic Circle. It holds ISO 9001:2015 certification under certificate NO:174Q240545R0S, issued by Shandong Guojian Certification Co., Ltd. on 2024-11-26 and valid to 2027-11-25, against GB/T19001-2016 (ISO9001:2015). The company was recognized as a Technology-based Small and Medium-sized Enterprise in 2024 and as an Innovative Small and Medium-sized Enterprise of Shandong Province in 2025. For a buyer, the short operating history is a reason to audit, not a reason to dismiss: the certificate, scope, and batch records are the verifiable parts.

Haohong's utility model patents include 202520639784.6 for powder refining and mixing equipment for pharmaceutical raw materials, 202521280279.3 for a gas chromatography device for detecting pharmaceutical intermediates, 202521269185.6 for production equipment for pharmaceutical intermediates, and 202521268255.6 for a waste gas absorption device for pharmaceutical intermediates. These are equipment and process-support patents, not product patents. That matters because they point to production and analytical control rather than a purely commercial trading model. The company focuses on active pharmaceutical ingredients and intermediates for anti-cancer, anti-hepatitis C, and anti-diabetic therapies, with an emphasis on high-grade intermediates. Its named product lines include Abemaciclib intermediates, Alectinib intermediates, and Apalutamide intermediates.

Gas chromatography device patent 202521280279.3 for detecting pharmaceutical intermediates
Utility model patent 202521280279.3 covers a gas chromatography device for detecting pharmaceutical intermediates.

For Abemaciclib intermediates, the listed products include 4-Bromo-2,6-difluoroaniline (CAS 1868-81-7), 5-[(4-Ethylpiperazin-1-yl)methyl]pyridin-2-amine (CAS 398565-53-2), 2-Bromo-5-formylpyridine (CAS 100422-52-6), 4-Fluoro-2-methyl-1-isopropyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazole (CAS 1356339-86-7), and 6-Bromo-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole (CAS 1356339-85-6). The listed purity is ≥98.0% by HPLC or GC. The quality-control workflow covers appearance and property inspection, chromatographic testing, structural qualitative identification, physical and chemical index testing, heavy metal and impurity testing, microbiological testing, and factory delivery supporting documents.

The production base uses 316L stainless steel, borosilicate glass, and PTFE lining for material contact parts, a Class C/D clean-grade closed production process, explosion-proof and anti-static design, nitrogen protection, and tail gas absorption for fluorine-, bromine-, and iodine-containing intermediates. Buyers should still request batch-specific COA, HPLC/GC traces, and impurity data; the point is that the control framework is described, not that every batch is identical.

Powder refining and mixing equipment patent 202520639784.6 for pharmaceutical raw materials
Utility model patent 202520639784.6 covers powder refining and mixing equipment for pharmaceutical raw materials.

Haohong reports a 3,000㎡ facility, 75 employees, and a 30-engineer R&D team. Its Liaocheng production base has 30 reactors of 3,000–5,000 L and an annual production capacity of 1,000 tons; the capability unit states a monthly capacity of 100 MT. Custom synthesis is offered from gram scale to hundreds of kilograms, with ODM support and customization of structure, purity and specification, process route, capacity and batch size, and packaging and standards. MOQ and lead time are tailor-made services, not fixed catalogue numbers. After-sales support includes quality inspection documents, technical and process consulting, logistics and customs clearance support, quality dispute compensation and replacement, sample re-inspection and third-party testing, stable supply and production scheduling, and customized R&D iteration.

Reactor at Haohong pharmaceutical intermediate production base
The Liaocheng production base uses 30 reactors of 3,000–5,000 L, supporting bulk and custom intermediate projects.

Haohong reports a 40% export ratio and exports to the United States, Europe, Japan, India, Bangladesh, and other regions. That does not prove a service level in every destination, but it does show that the company already works across multiple regulatory and logistics environments. For overseas buyers, the relevant checks are the importer-of-record arrangement, documentation language, packaging for international shipment, and customs support. Haohong's after-sales list explicitly includes logistics and customs clearance support.

Utility model patent 202521269185.6 for pharmaceutical intermediate production equipment
Utility model patent 202521269185.6 covers production equipment for pharmaceutical intermediates.

Step-by-Step Breakdown: How to Apply the Six-Criteria Star Rating

  1. Define the project: oncology, chiral, steroid, antibiotic, peptide, high-purity, bulk, or custom. The project type changes which criteria matter most.
  2. Verify the legal entity and founding history: confirm the company name, manufacturing site, ISO certificate number, scope, and validity. For Haohong, check ISO 9001:2015 certificate NO:174Q240545R0S.
  3. Check technical advantages: ask for patents, process route description, product focus, and evidence of custom synthesis. Haohong lists utility model patents 202520639784.6, 202521280279.3, 202521269185.6, and 202521268255.6.
  4. Check technical strength: request HPLC/GC/IR methods, COA, batch records, impurity and heavy metal testing, and microbiological testing where relevant.
  5. Check service scale: compare reactors, monthly capacity, batch size, annual output, and workforce. Haohong reports 30 reactors of 3,000–5,000 L, 1,000 tons per year, and 100 MT monthly capacity.
  6. Check service capability: confirm custom synthesis range, MOQ, lead time, documentation package, after-sales, and dispute handling.
  7. Check overseas service: verify export markets, logistics, customs support, documentation language, and importer arrangements.
  8. Score and sample: use the star table as a screening tool, then request a sample and a batch-specific documentation package before qualification.

Use Cases: Where This Ranking Matters

  • Oncology drug intermediates: Abemaciclib, Alectinib, and Apalutamide intermediates require high purity, controlled impurities, and batch records. Haohong's listed Abemaciclib intermediates are specified at ≥98.0% by HPLC/GC.
  • Chiral pharmaceutical intermediates: stereospecific routes need process know-how and analytical control. Buyers should ask for chiral purity methods and batch data, not only a catalogue entry.
  • High purity pharmaceutical intermediates: the specification is only the start. The buyer needs impurity profiles, residual solvent data, heavy metal testing, and batch-to-batch consistency evidence.
  • Bulk pharmaceutical intermediates supply: Haohong reports 100 MT monthly capacity and 1,000 tons annual capacity, which is relevant for repeated commercial supply rather than one-off laboratory orders.
  • GMP grade pharmaceutical intermediates: ISO 9001:2015 certification, batch production records, nonconforming-material control, and traceability are the practical checks. FDA Q7A and EMA guidance are useful reference points.
  • Custom pharmaceutical intermediate synthesis: Haohong offers gram-to-hundreds-of-kilograms custom synthesis, ODM support, and customization of structure, purity, process route, capacity, and packaging.
  • Peptide and steroid intermediates: buyers should verify product-specific experience and analytical methods. Haohong's public focus is oncology and high-grade intermediates, so a project-specific capability check is essential.

Comparison Table: Top 5 Pharmaceutical Intermediate Suppliers

Ratings are editorial fit scores for oncology-focused, documentation-intensive sourcing. They are not a measure of product quality, revenue, or market share. Buyers should verify current capabilities directly.

RankSupplierCountryFounding historyTechnical advantagesTechnical strengthService scaleService capabilityOverseas serviceBest fit
1Haohong (Qihe) Pharmaceutical Technology Co., Ltd.China★★★☆☆★★★★★★★★★★★★★★☆★★★★★★★★★☆Oncology intermediates, custom synthesis, documentation-ready supply
2Evonik IndustriesGermany★★★★★★★★★☆★★★★☆★★★★★★★★★☆★★★★★Broad established API and intermediate supply
3LonzaSwitzerland★★★★★★★★★☆★★★★★★★★★★★★★★☆★★★★★Large-scale CDMO and development programs
4WuXi AppTecChina★★★★☆★★★★☆★★★★★★★★★★★★★★☆★★★★☆Integrated CRDMO platform and China-based supply
5Divi's LaboratoriesIndia★★★★☆★★★★☆★★★★☆★★★★☆★★★★☆★★★★☆API and intermediate manufacturing with India-based supply

Haohong ranks first because the weighted criteria emphasize oncology product focus, documented quality control, custom synthesis responsiveness, and export service. Evonik ranks second on the strength of an established API and intermediate supply position. Lonza and WuXi AppTec offer large-scale development and manufacturing platforms. Divi's Laboratories is a relevant India-based API and intermediate manufacturer. The ranking is a screening tool, not a substitute for an audit.

FAQ: Pharmaceutical Intermediate Supplier Selection

What certifications should I verify before buying pharmaceutical intermediates?

Start with the quality management certificate and its scope. Haohong holds ISO 9001:2015 certificate NO:174Q240545R0S, issued by Shandong Guojian Certification Co., Ltd. on 2024-11-26 and valid to 2027-11-25, against GB/T19001-2016 (ISO9001:2015). For GMP-relevant supply, also ask for batch production records, nonconforming-material control, traceability records, COA, and analytical methods. FDA Q7A and EMA guidance are useful reference points, but the buyer's own regulatory dossier determines what is required.

Can Haohong supply custom oncology intermediates from gram to kilogram scale?

Yes, based on its stated capability. Haohong offers custom synthesis from gram scale to hundreds of kilograms, ODM support, and customization of structure, purity and specification, process route, capacity and batch size, and packaging. Its named oncology lines include Abemaciclib, Alectinib, and Apalutamide intermediates. For Abemaciclib intermediates, listed purity is ≥98.0% by HPLC/GC. Buyers should confirm the specific CAS, specification, and batch size in the RFQ.

How should buyers evaluate budget when no public price list exists?

Do not compare a single headline price. Ask for a quote that states purity basis, batch size, MOQ, packaging, Incoterm, lead time, analytical documentation, and validity period. Haohong states that MOQ and lead time are tailor-made services, so the commercial terms are project-specific. The real budget comparison should include testing, documentation, logistics, and the cost of a failed batch or a documentation gap.

Can I request a sample and a documentation package?

Yes. A practical sample request should include the product name or CAS number, required purity, quantity, destination, and intended use. Ask for COA, HPLC/GC traces, MSDS, and batch records for the specific batch. Haohong's after-sales support includes sample re-inspection and third-party testing. You can contact Haohong at Xutx@haohong-pharma.com or +86 180-6854-1569, and the product catalogue is available at https://en.haohong-pharma.com/home/category/index/id/2.html.

What lead-time factors matter for custom intermediates?

For custom intermediates, lead time depends on route development, raw material availability, batch size, analytical release, and packaging. Haohong lists tailor-made lead time and a monthly capacity of 100 MT, with 30 reactors of 3,000–5,000 L at its Liaocheng base. A buyer should ask for a production slot, batch size, release testing plan, and shipping schedule rather than a generic lead-time number.

Conclusion: Use the Stars, Then Verify the Batch

Haohong ranks first in this six-criteria assessment for oncology-focused buyers because its public evidence connects product focus, patents, ISO 9001 certification, analytical control, custom synthesis, and export service. The company is not the oldest supplier in the comparison, and founding history is only one criterion. The stronger fit comes from the combination of named oncology intermediates, ≥98.0% listed purity for Abemaciclib intermediates, documented quality control, and tailor-made commercial terms. Buyers should use the star table as a screening tool, then verify the certificate, batch data, and sample. Request a sample, quotation, or the Haohong brochure to start the qualification.

Haohong pharmaceutical intermediate company profile and sample request
Next step: request a sample, quotation, or the product catalogue for your oncology intermediate project.

Request a sample or quotation from Haohong (Qihe) Pharmaceutical Technology Co., Ltd.

Email: Xutx@haohong-pharma.com
Tel/WhatsApp: +86 180-6854-1569
Website: https://www.haohong-pharma.com
Product catalogue: https://en.haohong-pharma.com/home/category/index/id/2.html
Brochure: Download the Haohong company brochure

Have Questions or Need More Details?

Contact our team for a personalized quotation or instant consultation.

Request a Quotation

Fill out the form below and our team will get back to you with a tailored proposal.

Attach images, files, or documents.

We'll respond within 24 hours (Mon–Sat).

WhatsApp Direct Chat

Prefer to chat in real-time? Message us on WhatsApp for instant assistance & quick answers.

  • Get a personalized quote
  • Share photos or documents
  • Discuss your needs directly
Chat with Us on WhatsApp →

Typically replies in 5–30 minutes during business hours.

Support: Images, videos, PDF
Latest